<?xml-stylesheet type='text/xsl' href='anzctrTransform.xsl'?>
<ANZCTR_Trial requestNumber="81897">
  <stage>Registered</stage>
  <submitdate>18/03/2009</submitdate>
  <approvaldate>8/05/2009</approvaldate>
  <actrnumber>ACTRN12609000233224</actrnumber>
  <trial_identification>
    <studytitle>A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers</studytitle>
    <scientifictitle>A Single-Dose Safety and Tolerability Placebo Controlled Study of Subcutaneous SCH 900222 in Healthy Volunteers</scientifictitle>
    <utrn />
    <trialacronym />
  </trial_identification>
  <conditions>
    <healthcondition>The use of SCH 900222 for autoimmune disorders.</healthcondition>
    <conditioncode>
      <conditioncode1>Inflammatory and Immune System</conditioncode1>
      <conditioncode2>Autoimmune diseases</conditioncode2>
    </conditioncode>
  </conditions>
  <interventions>
    <interventions>A single dose of either 50mg or 200mg SCH 900222 administered as a subcutaneous single injection.</interventions>
    <comparator>Subcutaneous single injection of placebo (saline solution).</comparator>
    <control>Placebo</control>
    <interventioncode>Treatment: drugs</interventioncode>
  </interventions>
  <outcomes>
    <primaryOutcome>
      <outcome>To determine the safety and tolerability of a rising single subcutaneous fixed dose of SCH 900222 in healthy subjects.
(Assessed via vital sign measurements, standard laboratory safety tests, urinalysis &amp;/or physical examinations)</outcome>
      <timepoint>Assessed throughout the study at each study visit between Days 1-140 (13 visits).</timepoint>
    </primaryOutcome>
    <secondaryOutcome>
      <outcome>To determine the relative bioavailability and pharmacokinetics of rising subcutaneous dose of SCH 900222 compared to parallel intravenous dosing in healthy subjects. (Assessed via pharmacokinetic (PK) blood sample analysis)</outcome>
      <timepoint>Assessed throughout the study at each study visit between Days 1-140 (13 visits).</timepoint>
    </secondaryOutcome>
  </outcomes>
  <eligibility>
    <inclusivecriteria>-Male/Female Healthy volunteers must have no history of latent or active tuberculosis (TB) prior to screening</inclusivecriteria>
    <inclusiveminage>18</inclusiveminage>
    <inclusiveminagetype>Years</inclusiveminagetype>
    <inclusivemaxage>45</inclusivemaxage>
    <inclusivemaxagetype>Years</inclusivemaxagetype>
    <inclusivegender>Both males and females</inclusivegender>
    <healthyvolunteer>Yes</healthyvolunteer>
    <exclusivecriteria>History of malignancy, Human Immunodeficiency Virus (HIV), Hepatitis B, Hepatitis C, active or latent mycobacterium tuberculosis</exclusivecriteria>
  </eligibility>
  <trial_design>
    <studytype>Interventional</studytype>
    <purpose>Treatment</purpose>
    <allocation>Randomised controlled trial</allocation>
    <concealment />
    <sequence />
    <masking />
    <assignment />
    <designfeatures />
    <endpoint />
    <statisticalmethods />
    <masking1 />
    <masking2 />
    <masking3 />
    <masking4 />
    <patientregistry />
    <followup />
    <followuptype />
    <purposeobs />
    <duration />
    <selection />
    <timing />
  </trial_design>
  <recruitment>
    <phase />
    <anticipatedstartdate>1/06/2009</anticipatedstartdate>
    <actualstartdate />
    <anticipatedenddate />
    <actualenddate />
    <samplesize>32</samplesize>
    <actualsamplesize />
    <recruitmentstatus>Recruiting</recruitmentstatus>
    <recruitmentcountry>Australia</recruitmentcountry>
    <recruitmentstate />
  </recruitment>
  <sponsorship>
    <primarysponsortype>Commercial sector/Industry</primarysponsortype>
    <primarysponsorname>Schering-Plough</primarysponsorname>
    <primarysponsoraddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033
USA</primarysponsoraddress>
    <primarysponsorcountry>Australia</primarysponsorcountry>
    <fundingsource>
      <fundingtype>Commercial sector/Industry</fundingtype>
      <fundingname>Schering-Plough</fundingname>
      <fundingaddress>2000 Galloping Hill Road
Kenilworth, New Jersey 07033
USA</fundingaddress>
      <fundingcountry>Australia</fundingcountry>
    </fundingsource>
    <secondarysponsor>
      <sponsortype>None</sponsortype>
      <sponsorname />
      <sponsoraddress />
      <sponsorcountry />
    </secondarysponsor>
  </sponsorship>
  <ethicsAndSummary>
    <summary>This study will evaluate the safety, tolerability, &amp; pharmacokinetic response to SCH 900222 subcutaneous fixed dose in healthy subjects.</summary>
    <trialwebsite />
    <publication />
    <ethicsreview>Approved</ethicsreview>
    <publicnotes />
    <ethicscommitee>
      <ethicname />
      <ethicaddress />
      <ethicapprovaldate />
      <hrec />
      <ethicsubmitdate>23/02/2009</ethicsubmitdate>
      <ethiccountry />
    </ethicscommitee>
  </ethicsAndSummary>
  <attachment />
  <contacts>
    <contact>
      <title />
      <name>Dr Peter Hodsman</name>
      <address>Centre for Clinical Studies
5th floor Burnet Tower
AMREP Precinct
89 Commercial Rd
Melbourne
VIC 3004</address>
      <phone>+61 3 9076 8960</phone>
      <fax />
      <email>p.hodsman@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Scientific Queries</type>
    </contact>
    <contact>
      <title />
      <name>Mary Franich</name>
      <address>Centre for Clinical Studies
5th floor Burnet Tower
AMREP Precinct
89 Commercial Rd
Melbourne
VIC 3004</address>
      <phone>1800-243-733</phone>
      <fax />
      <email>m.franich@nucleusnetwork.com.au</email>
      <country>Australia</country>
      <type>Public Queries</type>
    </contact>
    <contact>
      <title />
      <name>Catherine Rowland</name>
      <address>Schering-Plough
66 Waterloo Rd
North Ryde
NSW 2113</address>
      <phone>+61 2 8988 8130</phone>
      <fax />
      <email>catherine.rowland@spcorp.com</email>
      <country>Australia</country>
      <type>Updating Information</type>
    </contact>
    <contact>
      <title />
      <name />
      <address />
      <phone />
      <fax />
      <email />
      <country />
      <type>Principal Investigator</type>
    </contact>
  </contacts>
</ANZCTR_Trial>